bd 2

BD-AcAc 2 (Ketone Ester) is a ketone monoester and can be used as a source of oral nutritional ketones. BD-AcAc 2 can elevate plasma levels of acetoacetate and β-hydroxybutyrate, blood Na+, blood glucose levels and blood creatinine levels after oral administration in mice. BD-AcAc 2 can partly prevent muscle weakness in septic mice. BD-AcAc 2 exhibits potential to improve endurance and exercise performance in animal body. BD-AcAc 2 can also be used to research diabetes or Parkinson's disease.

(S,S)-BD-AcAc 2 ((S,S)-Ketone Ester), an (S,S)-enantiomer of BD-AcAc 2, increases AcAc and acetone levels, inducing sustained ketosis and significantly delaying seizures associated with central nervous system oxygen toxicity (CNS-OT).

BY27, a potent and selective BET BD2 inhibitor (Ki: 3.1 nM) with anticancer activity, inhibits BD1 BD2 of BRD2, BRD3, BRD4, and BRDT, and suppresses tumor growth.

GSK046 (iBET-BD2) is a potent, selective, and orally active BD2 bromodomain inhibitor of the BET proteins, with IC50 values of 264 nM [BRD2 BD2], 98 nM [BRD3 BD2], 49 nM [BRD4 BD2], and 214 nM [BRDT BD2], respectively. It exhibits immunomodulatory activity.

BD 1008 dihydrobromide is a selective antagonist of the sigma 1 (σ1) receptor (Ki = 2 nM). BD 1008 dihydrobromide have high affinity for sigma1 receptors, moderate affinity for sigma2 receptors.

BRD4-BD1 2-IN-1 is a highly effective inhibitor of BRD4, targeting the BRD4 BD-1 and BD-2 domains with IC50 values of <100 nM each (US20150148375A1, compound 5) [1].

BRD4 Inhibitor-23 is a potent, orally active BRD4 inhibitor that acts on BRD4 BD-1 (IC50: 6.21 nM) and BRD4 BD-2 (IC50: 1.44 nM).

BD 1008 Free Base is a selective sigma receptor antagonist, with a reported binding affinity of Kᵢ = 2 ± 1 nM for the sigma-1 receptor and 4 times selectivity over the sigma-2 receptor.